This site is intended for healthcare professionals outside the US

30 MG OF SANDOSTATIN® LAR®: THE MAJORITY OF PATIENTS ACHIEVED STABLE DISEASE AT 6 MONTHS1

Print |

67% achieved stable disease at 6 months vs 37% for placebo

The World Health Organization (WHO) response criteria for stable disease: A 50% decrease in total tumor size cannot be established, and a 25% increase in the size of one or more measurable lesions has not been demonstrated.2

Initiate 30 mg of Sandostatin® LAR® every 4 weeks for tumor control in patients with advanced midgut NET.3

67% (28/42) achieved stable disease at 6 months vs 37% (16/43) for placebo (N=85; P=0.0079).1

The recommended dose of Sandostatin® LAR® for tumor control in advanced midgut NET is 30 mg administered every 4 weeks. Treatment with Sandostatin® LAR® for tumor control should be continued in the absence of tumor progression.3

30 mg of Sandostatin® LAR®: The approved dose for tumor control.1

References:
1. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. 2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. 3. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2016.